Details for Patent: 9,763,941

Which drugs does patent 9,763,941 protect, and when does it expire?

Patent 9,763,941 protects BRAFTOVI and is included in one NDA.

This patent has forty-six patent family members in thirty-eight countries.

Summary for Patent: 9,763,941

Title:	Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
Abstract:	This invention relates to solid oral pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methyl -sulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (COMPOUND A) and the use of these formulations for treating proliferative diseases, such as solid tumor diseases.
Inventor(s):	Daya Verma, Yogita Krishnamachari, Xiaohong Shen, Hanchen Lee, Ping Li, Rajinder Singh, LayChoo Tan
Assignee:	Array Biopharma Inc
Application Number:	US15/179,190
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,763,941
Patent Claim Types: see list of patent claims	Use; Formulation; Dosage form;

Drugs Protected by US Patent 9,763,941

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-001	Jun 27, 2018		DISCN	Yes	No						TREATMENT OF MELANOMA
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-002	Jun 27, 2018		RX	Yes	Yes						TREATMENT OF MELANOMA

International Family Members for US Patent 9,763,941

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	088936
Australia	2012340759
Brazil	112014011981
Canada	2856406
Chile	2014001337
China	103945831